 Lineage Cell Therapeutics Inc NYSE: LCTX has announced that restoration of retinal tissue was observed in two additional patients enrolled in the Phase 12a study of its lead product candidate, OpRegen. OpRegen is an allogeneic retinal pigment epithelium RPE cell transplant therapy in development for the treatment of age-related macular degeneration AMD with geographic atrophy GA or dry atrophic AMD. 